Analysts See $-0.25 EPS for Agile Therapeutics, Inc. (AGRX)

February 15, 2018 - By Vivian Park

 Analysts See $ 0.25 EPS for Agile Therapeutics, Inc. (AGRX)
Investors sentiment increased to 1.35 in Q3 2017. Its up 0.74, from 0.61 in 2017Q2. It improved, as 9 investors sold Agile Therapeutics, Inc. shares while 8 reduced holdings. 11 funds opened positions while 12 raised stakes. 23.16 million shares or 7.44% more from 21.56 million shares in 2017Q2 were reported.
Susquehanna International Llp reported 15,211 shares. Aisling Ltd Llc holds 1.32% or 1.80M shares in its portfolio. Falcon Point Limited reported 0.06% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Moreover, Commonwealth Of Pennsylvania School Empls Retrmt has 0% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX). The Sweden-based Investor has invested 1.01% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Northern Tru Corp accumulated 28,097 shares. Janney Montgomery Scott Ltd Liability Company has invested 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Millennium Mngmt Ltd Liability Com owns 143,326 shares for 0% of their portfolio. Renaissance Ltd Liability Com reported 88,500 shares. Bridgeway Capital Management reported 0.01% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Proquest Assocs Iv Lc has invested 22.62% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Art Advsr Ltd Llc invested in 15,512 shares or 0% of the stock. Bnp Paribas Arbitrage stated it has 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Glenmede Tru Na reported 0% stake. Caxton reported 1.82 million shares or 8.26% of all its holdings.

Analysts expect Agile Therapeutics, Inc. (NASDAQ:AGRX) to report $-0.25 EPS on March, 14.They anticipate $0.04 EPS change or 13.79 % from last quarter’s $-0.29 EPS. After having $-0.22 EPS previously, Agile Therapeutics, Inc.’s analysts see 13.64 % EPS growth. The stock decreased 1.08% or $0.04 during the last trading session, reaching $3.66. About 68,415 shares traded. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 48.71% since February 15, 2017 and is downtrending. It has underperformed by 65.41% the S&P500.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage

Among 6 analysts covering Agile Therapeutics (NASDAQ:AGRX), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Agile Therapeutics had 21 analyst reports since December 30, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, January 8 by Cantor Fitzgerald. On Thursday, November 9 the stock rating was maintained by Noble Financial with “Buy”. The rating was downgraded by William Blair on Friday, December 22 to “Hold”. As per Thursday, October 12, the company rating was maintained by H.C. Wainwright. Noble Financial initiated Agile Therapeutics, Inc. (NASDAQ:AGRX) on Wednesday, December 30 with “Buy” rating. The firm earned “Hold” rating on Friday, December 22 by Janney Capital. As per Friday, December 22, the company rating was maintained by Noble Financial. Cantor Fitzgerald maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) rating on Tuesday, October 10. Cantor Fitzgerald has “Buy” rating and $8.0 target. The stock of Agile Therapeutics, Inc. (NASDAQ:AGRX) earned “Buy” rating by Noble Financial on Monday, June 12. On Monday, October 2 the stock rating was reinitiated by H.C. Wainwright with “Buy”.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $125.12 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

More important recent Agile Therapeutics, Inc. (NASDAQ:AGRX) news were published by: which released: “Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla …” on October 31, 2017, also published article titled: “Agile Therapeutics: Sell-Off Post CRL Makes It Worth A Look”, published: “Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual …” on September 07, 2017. More interesting news about Agile Therapeutics, Inc. (NASDAQ:AGRX) was released by: and their article: “Agile Therapeutics: Is This ~$3.50 ‘Busted IPO’ Worthy Of Investment …” with publication date: September 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.